European CHMP positive opinion for licence extension for Epclusa (sofosbuvir/velpatasvir) in hepatitis C infection

The recommended license extension is for treatment of chronic hepatitis C virus (HCV) infection in patients aged 3 years of age and older. A new granules formulation is recommended for approval. It is currently licensed for patients aged 6 years and over.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news